Pharma greed - US vs UK?

ByeByeBackfat said:

Wegovy with a GoodRx coupon is around $350 a month at the highest dose! It's less at lower doses. Just Google 'GoodRx Wegovy Coupon' and show it to the pharmacy. They can tell you the price before filling it. Good luck!

Click to expand...

If you don't have government insurance, use the Ozempic savings card too: https://www.ozempic.com/savings-and-resources/save-on-ozempic.html. GoodRx works as well: https://www.goodrx.com/ozempic

Danielle_Path said:

If you don't have government insurance, use the Ozempic savings card too: https://www.ozempic.com/savings-and-resources/save-on-ozempic.html. GoodRx works as well: https://www.goodrx.com/ozempic

Click to expand...

Make sure they run it as self-pay when you use the card. My insurance covered it, but I had a huge deductible. The card only saved me $100 when processed through insurance. Calling the company and running it as self-pay made a big difference.

Check out the hot pepper group if you're interested—details are linked there.

US pricing reflects a no-negotiation structure - the UK floor is the counter-example. Different rules, not just spin.

the drug pricing policy pressure on Canada is a real variable for anyone tracking cross-border pharmaceutical access - the political push to raise Canadian prices as a lever for lowering US prices has been a consistent feature of recent US trade negotiations and has implications for what the Canadian access pathway looks like in 12-24 months. the generic access window that exists now may tighten depending on how that negotiation resolves

the US-specificity of the pricing article reflects the genuine pricing isolation the US pharmaceutical market operates under - the reference pricing systems in most European countries cap what manufacturers can charge in a way that the US system does not. the worst-in-Europe comment from the manufacturer is the inverse of the same situation; a country with strong reference pricing produces lower revenue for the manufacturer and lower cost for the patient

the taxpayer-funded research converted to private monopoly pricing is one of the more straightforward critiques of how pharmaceutical development is structured - the public funding of basic and early-stage research that makes drug development possible does not translate into any pricing constraint on the resulting products. the return on that public investment flows almost entirely to shareholders rather than to the population that funded it